A 48-year-old woman with H. pylori–positive duodenal ulcer disease presents for eradication therapy. She has no drug allergies and normal renal function. What is the preferred first-line regimen for H. pylori eradication in India?

## First-Line H. pylori Eradication Regimen **Key Point:** In India, amoxicillin + clarithromycin + omeprazole (PPI-based triple therapy) remains the **guideline-recommended first-line regimen** for H. pylori eradication per INASL (Indian National Association for Study of the Liver) and GSIDC guidelines, with eradication rates of 85–90% when compliance is good. However, clarithromycin resistance is rising (20–30% in some Indian regions), and clinicians should be aware of this trend. ### Standard Triple Therapy Regimen **Dosing:** - Omeprazole: 20 mg twice daily (or lansoprazole 30 mg BD / esomeprazole 40 mg OD) - Amoxicillin: 1 g twice daily - Clarithromycin: 500 mg twice daily - **Duration:** 7–14 days (7–10 days commonly used in India) ### Comparative Overview of Regimens | Feature | Triple Therapy (Amox + Clari + PPI) | Bismuth Quadruple | Sequential Therapy | |---------|-------------------------------------|-------------------|--------------------| | **Eradication rate** | 85–90% | 90–95% | 90–95% | | **Complexity** | Simple (3 drugs) | Moderate (4 drugs) | Complex (2-phase) | | **Cost** | Low | Higher (bismuth) | Moderate | | **Compliance** | Good | Moderate | Poor | | **First-line (India)** | **Yes (guideline-recommended)** | Rescue/high-resistance areas | Rescue | | **Resistance concern** | Clarithromycin resistance rising | Overcomes clarithromycin resistance | Partially overcomes resistance | **High-Yield:** Triple therapy is recommended as first-line by: - **INASL / GSIDC** (Indian guidelines) - **ACG** (American College of Gastroenterology) - **Maastricht V / Florence Consensus** (in regions with clarithromycin resistance <15–20%) ### Rising Resistance — An Important Caveat Clarithromycin resistance in India has been reported at **20–30% in some urban centres**, which is approaching the threshold (>20%) at which many international guidelines recommend switching to bismuth-based quadruple therapy as first-line. Despite this, **current Indian guidelines still endorse triple therapy as first-line** for most patients, reserving quadruple therapy for: 1. Known or suspected clarithromycin resistance 2. Previous macrolide exposure 3. Rescue therapy after triple therapy failure ### When to Use Alternatives 1. **Quadruple therapy** (bismuth subsalicylate + tetracycline + metronidazole + PPI): - Clarithromycin resistance >20% in the region - Previous macrolide exposure - Second-line rescue therapy 2. **Sequential therapy** (PPI + amoxicillin × 5 days → PPI + clarithromycin + tinidazole × 5 days): - High clarithromycin resistance (>25%) - Complex regimen with poor compliance; not first-line 3. **Levofloxacin-based regimens** (Option D): - Rescue therapy only (third-line) - Not first-line due to rising fluoroquinolone resistance in India 4. **Omeprazole + amoxicillin + metronidazole** (Option C): - Older regimen; lower eradication rates (~70–75%) - Not recommended as first-line in current guidelines **Clinical Pearl:** While clarithromycin resistance is rising in India, triple therapy (amoxicillin + clarithromycin + PPI) remains the **guideline-endorsed first-line choice** because it is simple, affordable, and effective in the majority of patients. Bismuth quadruple therapy is the preferred rescue or alternative in high-resistance settings. Clinicians should monitor local resistance patterns and consider susceptibility testing in treatment failures. **Mnemonic:** **ACE** for first-line H. pylori eradication: - **A**moxicillin - **C**larithromycin - **E**someprazole / omeprazole [cite: Harrison's Principles of Internal Medicine, 21e, Ch 297; INASL Consensus Guidelines on H. pylori; Maastricht V/Florence Consensus Report, Gut 2017]